Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$58.09
At close: May 28, 5:31 PM EDT
$59.00
0.911.57%
After Hours: 5:31 PM EDT
Comments
Loading...
Biomarin Pharmaceutical Analyst Ratings and Price Targets | NASDAQ:BMRN | Benzinga
Biomarin Pharmaceutical Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Biomarin Pharmaceutical Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Citigroup
Oppenheimer
Scotiabank
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Biomarin Pharmaceutical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/05/2025 | Buy Now | — | Goldman Sachs | Salveen Richter53% | $124 → $104 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | — | Citigroup | David Lebovitz65% | $82 → $78 | Maintains | Neutral | Get Alert |
| 02/24/2025 | Buy Now | — | Oppenheimer | Leland Gershell67% | → $98 | Upgrade | Perform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | — | Scotiabank | George Farmer38% | $78 → $80 | Maintains | Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | — | Citigroup | David Lebovitz65% | $81 → $82 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | — | RBC Capital | Luca Issi42% | $70 → $70 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/20/2025 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | — | UBS | Eliana Merle43% | $109 → $113 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $122 → $126 | Maintains | Overweight | Get Alert |
| 02/20/2025 | Buy Now | — | B of A Securities | Geoff Meacham61% | $99 → $103 | Maintains | Buy | Get Alert |
| 12/12/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2024 | Buy Now | — | Wolfe Research | Akash Tewari41% | → $95 | Initiates | → Outperform | Get Alert |
| 10/30/2024 | Buy Now | — | Citigroup | David Lebovitz65% | $93 → $81 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | $93 → $84 | Maintains | Hold | Get Alert |
| 10/30/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $110 → $90 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | — | JP Morgan | Jessica Fye63% | $110 → $109 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $80 → $80 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/30/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov68% | $115 → $105 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | — | UBS | Eliana Merle43% | $104 → $106 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | — | Baird | Joel Beatty67% | $72 → $65 | Maintains | Neutral | Get Alert |
| 10/30/2024 | Buy Now | — | William Blair | Tim Lugo31% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill43% | → $79 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $85 → $80 | Maintains | Sector Perform | Get Alert |
| 10/04/2024 | Buy Now | — | Barclays | Gena Wang50% | $110 → $86 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | — | Scotiabank | George Farmer38% | $95 → $78 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | — | Truist Securities | Joon Lee76% | $118 → $90 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $115 → $90 | Maintains | Overweight | Get Alert |
| 09/17/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $100 → $85 | Maintains | Sector Perform | Get Alert |
| 09/17/2024 | Buy Now | — | B of A Securities | Geoff Meacham61% | $130 → $115 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | — | Stifel | Paul Matteis43% | $115 → $87 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | — | Bernstein | William Pickering38% | $116 → $90 | Maintains | Outperform | Get Alert |
| 09/13/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | $93 → $93 | Maintains | Hold | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2024 | Buy Now | — | JP Morgan | Jessica Fye63% | $111 → $120 | Maintains | Overweight | Get Alert |
| 09/05/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | — | Scotiabank | George Farmer38% | $86 → $95 | Maintains | Sector Perform | Get Alert |
| 09/05/2024 | Buy Now | — | Truist Securities | Joon Lee76% | $140 → $118 | Maintains | Buy | Get Alert |
| 09/05/2024 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $107 → $122 | Maintains | Overweight | Get Alert |
| 08/27/2024 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $107 → $107 | Maintains | Overweight | Get Alert |
| 08/21/2024 | Buy Now | — | Stifel | Paul Matteis43% | $112 → $115 | Maintains | Buy | Get Alert |
| 08/20/2024 | Buy Now | — | Bernstein | William Pickering38% | $94 → $110 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/06/2024 | Buy Now | — | TD Cowen | Phil Nadeau66% | $125 → $120 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | — | Scotiabank | George Farmer38% | $85 → $86 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | — | Stifel | Paul Matteis43% | $108 → $112 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | — | Barclays | Gena Wang50% | $111 → $110 | Maintains | Overweight | Get Alert |
| 08/06/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov68% | $113 → $115 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 07/25/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | $89 → $89 | Maintains | Hold | Get Alert |
| 07/22/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 06/27/2024 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $110 → $115 | Maintains | Overweight | Get Alert |
| 05/17/2024 | Buy Now | — | Baird | Joel Beatty67% | $104 → $72 | Downgrade | Outperform → Neutral | Get Alert |
| 05/14/2024 | Buy Now | — | Evercore ISI Group | Cory Kasimov68% | → $113 | Initiates | → Outperform | Get Alert |
| 04/26/2024 | Buy Now | — | Morgan Stanley | Matthew Harrison61% | $115 → $112 | Maintains | Overweight | Get Alert |
| 04/26/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | $91 → $89 | Maintains | Hold | Get Alert |
| 04/25/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $110 → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/25/2024 | Buy Now | — | Citigroup | David Lebovitz65% | $94 → $91 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | — | Scotiabank | George Farmer38% | $83 → $85 | Maintains | Sector Perform | Get Alert |
| 04/25/2024 | Buy Now | — | Wells Fargo | Mohit Bansal67% | $100 → $110 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | → $91 | Reiterates | Hold → Hold | Get Alert |
| 02/23/2024 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $100 → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | — | RBC Capital | Luca Issi42% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/23/2024 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $115 → $107 | Maintains | Overweight | Get Alert |
| 01/30/2024 | Buy Now | — | Baird | Joel Beatty67% | $127 → $104 | Maintains | Outperform | Get Alert |
| 12/21/2023 | Buy Now | — | Stifel | Paul Matteis43% | → $101 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | — | RBC Capital | Luca Issi42% | $100 → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/03/2023 | Buy Now | — | BMO Capital | Kostas Biliouris34% | $102 → $100 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $125 → $115 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | — | Morgan Stanley | Matthew Harrison61% | $125 → $117 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | — | Barclays | Gena Wang50% | $125 → $111 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | — | Bernstein | William Pickering38% | → $82 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/16/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | — | Raymond James | Laura Chico49% | — | Initiates | → Market Perform | Get Alert |
| 09/25/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas54% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | — | UBS | Martin Auster55% | → $120 | Initiates | → Buy | Get Alert |
| 09/15/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas54% | → $140 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | — | Guggenheim | Debjit Chattopadhyay52% | → $110 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | — | RBC Capital | Luca Issi42% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 09/13/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | — | Morgan Stanley | Matthew Harrison61% | $129 → $125 | Maintains | Overweight | Get Alert |
| 08/01/2023 | Buy Now | — | Stifel | Paul Matteis43% | $118 → $108 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | $73 → $70 | Maintains | Neutral | Get Alert |
| 08/01/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer52% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | Buy Now | — | RBC Capital | Luca Issi42% | → $100 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/27/2023 | Buy Now | — | Scotiabank | George Farmer38% | → $95 | Initiates | → Sector Perform | Get Alert |
| 07/21/2023 | Buy Now | — | B of A Securities | Geoff Meacham61% | $200 → $185 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | — | BMO Capital | Kostas Biliouris34% | → $102 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/03/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem55% | $110 → $104 | Maintains | Hold | Get Alert |
| 06/30/2023 | Buy Now | — | Citigroup | David Lebowitz53% | $103 → $96 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | — | Baird | Joel Beatty67% | → $127 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | $69 → $73 | Maintains | Neutral | Get Alert |
| 06/30/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas54% | $125 → $140 | Maintains | Buy | Get Alert |
| 06/14/2023 | Buy Now | — | Credit Suisse | Tiago Fauth44% | → $120 | Assumes | → Outperform | Get Alert |
| 04/27/2023 | Buy Now | — | Citigroup | David Lebowitz53% | $114 → $103 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | — | Guggenheim | Debjit Chattopadhyay52% | $125 → $120 | Maintains | Buy | Get Alert |
| 04/27/2023 | Buy Now | — | Piper Sandler | Christopher Raymond55% | $128 → $125 | Maintains | Overweight | Get Alert |
| 04/27/2023 | Buy Now | — | RBC Capital | Luca Issi42% | → $100 | Reiterates | → Sector Perform | Get Alert |
| 04/27/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | $74 → $69 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Biomarin Pharmaceutical (BMRN) stock?
The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Goldman Sachs on May 5, 2025. The analyst firm set a price target for $104.00 expecting BMRN to rise to within 12 months (a possible 76.27% upside). 51 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?
The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Goldman Sachs, and Biomarin Pharmaceutical maintained their buy rating.
When was the last upgrade for Biomarin Pharmaceutical (BMRN)?
The last upgrade for Biomarin Pharmaceutical Inc happened on February 24, 2025 when Oppenheimer raised their price target to $98. Oppenheimer previously had a perform for Biomarin Pharmaceutical Inc.
When was the last downgrade for Biomarin Pharmaceutical (BMRN)?
The last downgrade for Biomarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on May 5, 2025 so you should expect the next rating to be made available sometime around May 5, 2026.
Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?
While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a maintained with a price target of $124.00 to $104.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $59.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
